

**IN THE SPECIFICATION**

Please replace paragraph [001] of the specification with the following amended paragraph:

[001] This application is a 371 National Stage of International Application No. PCT/US2004/036200 filed on November 1, 2004, which designated the U.S., and which claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 60/516,172 filed on October 30, 2003, the entirety of which is incorporated herein by reference. The present application claims priority under 35 U.S.C. 119(e) to U.S. provisional application No. 60/516,172, filed October 30, 2003, and which is herein incorporated by reference in its entirety.

Please replace paragraph [009] of the specification with the following amended paragraph:

[009] In one preferred embodiment, the siRNAs are selected from the group consisting of hFas siRNA 1 (beginning at nucleotide 457) 5'-GAGGAAGACTGTTACTACA-3' [SEQ ID NO: 15], hFas siRNA 2 (beginning at nucleotide 667) 5'-TGATGAAGGACATGGCTTA-3' [SEQ ID NO: 16], hFas siRNA 3 (beginning at nucleotide 1211) 5'-GAAGCGTATGACACATTGA-3' [SEQ ID NO: 17], and hFas siRNA 4 (beginning at nucleotide 1294) 5'-GGACATTACTAGTGACTCA-3' [SEQ ID NO: 18].